Precipio, Inc. (PRPO)
NASDAQ: PRPO · IEX Real-Time Price · USD
5.00
-0.38 (-7.06%)
Jul 2, 2024, 4:30 PM EDT - Market closed
Company Description
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States.
It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.
It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
Precipio, Inc.
| Country | United States |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Ilan Danieli |
Contact Details
Address: 12325 Emmet St Omaha, Nebraska 68164 United States | |
| Phone | 203 787 7888 |
| Website | precipiodx.com |
Stock Details
| Ticker Symbol | PRPO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001043961 |
| CUSIP Number | 74019L503 |
| ISIN Number | US74019L6020 |
| Employer ID | 91-1789357 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Ilan Danieli | Founder, President, Chief Executive Officer and Director |
| Dr. Ayman A. Mohamed M.D. | Chief Technology Officer |
| Matthew Gage | Chief Financial Officer |
| Ahmed Zaki Sabet | Chief Operating Officer |
| Miri Chiko-Radomski | Chief Legal Counsel and People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2024 | 8-K | Current Report |
| Jun 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 6, 2024 | 8-K | Current Report |
| May 1, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2024 | 424B5 | Filing |